Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia

[1] Leeksma AC(2019)Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia Leukemia 33 390-402

[2] Taylor J(2016)B cell receptor inhibition as a target for CLL therapy Best Pract Res Clin Haematol 29 2-14

[3] Wu B(2017)Current status of Bruton’s tyrosine kinase inhibitor development and use in B-cell malignancies Drugs Aging 34 509-527

[4] Gardner JR(2011)The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia Blood. 117 563-574

[5] He J(2014)Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL Blood. 123 3286-3295

[6] Nahas M(2016)Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study Lancet Oncol 17 1409-1418

[7] Gonen M(2019)Long-term follow-up of the RESONATE phase 3 trial of ibrutinib versus ofatumumab Blood 133 2031-2042

[8] Alemayehu WG(2019)Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis Am J Hematol 94 554-562

[9] te Raa D(2019)Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia Blood 133 1011-1019

[10] Walther T(2018)Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL N Engl J Med 379 2517-2528

[1] Leeksma AC(2019)Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia Leukemia 33 390-402

[2] Taylor J(2016)B cell receptor inhibition as a target for CLL therapy Best Pract Res Clin Haematol 29 2-14

[3] Wu B(2017)Current status of Bruton’s tyrosine kinase inhibitor development and use in B-cell malignancies Drugs Aging 34 509-527

[4] Gardner JR(2011)The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia Blood. 117 563-574

[5] He J(2014)Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL Blood. 123 3286-3295

[6] Nahas M(2016)Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study Lancet Oncol 17 1409-1418

[7] Gonen M(2019)Long-term follow-up of the RESONATE phase 3 trial of ibrutinib versus ofatumumab Blood 133 2031-2042

[8] Alemayehu WG(2019)Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis Am J Hematol 94 554-562

[9] te Raa D(2019)Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia Blood 133 1011-1019

[10] Walther T(2018)Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL N Engl J Med 379 2517-2528